| Mar. 2005 |
SymBio Pharmaceuticals Limited established at Nishi-Shimbashi, Minato-ku, Tokyo |
| Jul. 2005 |
Head office relocates to Shimbashi, Minato-ku, Tokyo |
| Dec. 2005 |
License Agreement finalized with Astellas Pharma GmbH for SyB L-0501 (bendamustine) development & commercialization rights in Japan |
| Mar. 2006 |
Manufacturer's License (packaging, labeling and storage) obtained from Tokyo Metropolitan Government |
| Mar. 2007 |
License Agreement finalized with Astellas Deutschland GmbH for SyB L-0501 (bendamustine) development & commercialization rights in China (HK), Taiwan, Korea and Singapore |
| Aug. 2008 |
License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Japan |
| Mar. 2009 |
SymBio Pharmaceuticals concludes Sublicense Agreement with Cephalon, Inc. for development and commercialization rights of bendamustine hydrochloride in China (HK) |
| May 2009 |
License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Korea and Singapore |
| Oct. 2010 |
Received Domestic Manufacturing and Marketing Approval for Anticancer Agent TREAKISYM® |
| Dec. 2010 |
Launched domestic sales of anticancer agent TREAKISYM |
| July 2011 |
Onconova and SymBio Pharmaceuticals complete License Agreement for SyB L-1101/SyB C-1101 |
| Oct. 2011 |
Listed on Osaka Securities Exchange JASDAQ Growth Market (Now listed on Tokyo Stock Exchange) |
| Nov. 2014 |
Head office relocates to Toranomon, Minato-ku, Tokyo |
| May 2016 |
SymBio Pharma USA, Inc. established at Menlo Park, California, USA (Now registered in North Carolina) |
| Aug. 2016 |
Approval for Domestic Manufacturing and Marketing of Anticancer Agent TREAKISYM® for Additional Indication of Chronic Lymphocytic Leukemia |
| Dec. 2016 |
SymBio Pharmaceuticals announces the NDA approval of TREAKISYM ®(bendamustine) for the additional indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma in Japan |
| Sep. 2017 |
Eagle Pharmaceuticals (NASDAQ: EGRX) and SymBio Pharmaceuticals completed License Agreement for bendamustine liquid formulations (RTD Injection and RI Injection) development & commercialization rights in Japan *RTD: Ready-to-dilute, RI: Rapid Infusion |
| Sep. 2019 |
Entered into an exclusive global licensing agreement with Chimerix (USA) for the development, sales, and manufacturing of the antiviral drug "brincidofovir" (excluding smallpox) |
| Sep. 2020 |
SymBio Pharmaceuticals receives approval of TREAKISYM®Ready-To-Dilute (RTD) formulation |
| Dec. 2020 |
Commencement of in-house sales of the anti-cancer agent TREAKISYM® |
| Jan. 2021 |
Market Launch of TREAKISYM®Ready-To-Dilute (RTD) Formulation |
| Mar. 2021 |
SymBio Pharmaceuticals receives approval of TREAKISYM® for combination therapy |
| Apr. 2021 |
SymBio Pharmaceuticals receives approval of TREAKISYM® Ready To Dilute (RTD) Formulation for combination therapy |
| Feb. 2022 |
SymBio Pharmaceuticals receives approval of 10-minute Rapid Infusion (RI) administration of the TREAKISYM®Liquid Formulation |
| Mar. 2023 |
Signed a joint research and development agreement (CRADA) with NIH/NINDS |
| Dec. 2023 |
Relocated headquarters to Toranomon, Minato-ku, Tokyo |
| Oct. 2025 |
SymBio Pharmaceuticals and Nippon Steel Chemical & Material CO., LTD., were granted a co-filed patent for an immunoassay method (and an immunoassay device) |